Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment The PINES Randomized Clinical Trial 치료가 필요한 새로 진단된 소아 면역성 혈소판 감소증에 대한 엘트롬보파그(Eltrombopag)의 효과 PINES 무작위 임상시험
Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment The PINES Randomized Clinical Trial JAMA 334(20):p 1816-1826, November 25, 2025. | DOI: 10.1001/jama.2025.18168 Eltrombopag, a thrombopoietin receptor agonist, is approved by the US Food and Drug Administration for children with chronic immune thrombocytopenia. Efficacy of eltrombopag … Continued